Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Research output: Contribution to journalReviewResearchpeer-review

  1. Herpes simplex-virusinfektion hos nyfødte

    Research output: Contribution to journalReviewResearchpeer-review

  2. Ludomani som bivirkning til lavdosis af pramipexol ved behandling af restless legs syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Myokarditis og udvikling af dilateret kardiomyopati

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lokal immunpatologi ved COVID-19-associeret lungesvigt

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Recidiverende meningokoksygdom hos kvinde med mutation i C8B-genet

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

Translated title of the contributionSGLT2 inhibitorsfor treatment of chronic kidney disease without diabetes or heart failure
Original languageDanish
Article numberV11210887
JournalUgeskrift for Laeger
Volume184
Issue number16
ISSN0041-5782
Publication statusPublished - 18 Apr 2022

ID: 77651653